WO2016054959A1

WO2016054959A1 - Crystal form of bisulfate of jak inhibitor and preparation method therefor

Info

Publication number: WO2016054959A1
Application number: PCT/CN2015/089223
Authority: WO
Inventors: 孙飘扬; 武乖利; 高晓晖; 陈永江; 沈灵佳
Original assignee: 江苏恒瑞医药股份有限公司
Priority date: 2014-10-09
Filing date: 2015-09-09
Publication date: 2016-04-14
Also published as: PT3205653T; TW201613931A; CA2963581A1; JP6830888B2; RU2017114689A3; BR112017005564A2; CN105566327A; EP3205653A4; EP3205653B1; US20180237438A1; CN105980389B; KR20170057441A; RU2017114689A; US10150770B2; EP3205653A1; JP2017530146A; CA2963581C; TWI675839B; HUE052924T2; AU2015330554A1

Abstract

Provided is an I-type crystal of a JAK (Janus Kinase) inhibitor (3aR,5s,6aS)-N-(3-methoxyl-1,2,4-thiadiazole-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-formamide bisulfate represented by formula (I), and a preparation method therefor. The preparation method comprises crystallizing any crystal form of or amorphous compound solid of formula (I) in a single organic solvent to obtain the I-type crystal; this crystal has excellent crystal stability and chemical stability, and the crystal solvent used is low in toxicity and residues, making the compound better applicable to clinical treatment.

Description

Crystal form of hydrogen sulfate of JAK kinase inhibitor and preparation method thereof

Technical field

The present invention relates to (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3- Form I crystal of d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogensulfate, and a preparation method and use thereof. The compounds of formula (I) obtained according to the process of the invention are useful in the treatment of arthritis.

Background technique

Arthritis is the most common chronic disease in the world, causing many causes of arthritis and causing joint damage. Currently, Tofacitinib (CP-690550) is a new oral JAK pathway inhibitor developed by Pfizer Inc. Tofacitinib is the first-in-class drug developed for the treatment of rheumatoid arthritis. Since the birth of tofacitinib in Pfizer's own laboratory, the drug has been placed on the high hopes of heavy drugs, the success of the drug will also be a major victory for Pfizer's highly criticized R & D business, after the results of the clinical phase III trial, Pfizer tofacitinib is significantly more effective than methotrexate.

Based on the structure of tofacitinib, a series of JAK kinase inhibitor compounds with in vivo and exogenous activity and high absorption have been developed, see WO2013091539. After screening according to the compound in WO2013091539 and preparing a salt, (3aR, 5s, 6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl) represented by the formula (I) is obtained. 5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogensulfate, the preparation method thereof Applicant's prior PCT patent application PCT/CN2014/076794, formula (I) Compounds are expected to be preferred compounds for JAK kinase inhibitors and have important research implications for the treatment of rheumatoid arthritis and rheumatoid arthritis.

The crystal structure of the pharmaceutically active ingredient often affects the chemical stability of the drug, and the difference in crystallization conditions and storage conditions may lead to changes in the crystal structure of the compound, sometimes accompanied by the formation of other forms of crystal form. In general, amorphous drug products have no regular crystal structure and often have other defects, such as poor product stability, fine crystallization, difficult filtration, easy agglomeration, and poor fluidity. Therefore, it is necessary to improve the various aspects of the above products. We need to study in depth to find new crystal forms with high purity and good chemical stability.

Summary of the invention

It is an object of the present invention to provide a stable crystalline form of a compound of formula (I) and a process for preparing the crystalline form.

We have investigated a series of crystalline products obtained by the compound of formula (I) under different crystallization conditions. The obtained crystalline product was subjected to X-ray diffraction and DSC detection, and it was found that the compound of formula (I) can be obtained under conventional crystallization conditions. The crystal form with good stability, we call it type I crystal. The DSC pattern of the type I crystal in the present application shows a melting endothermic peak near 220 ° C, and the X-ray powder diffraction pattern is shown in Fig. 1, using Cu-Ka radiation, at 2θ angle and interplanar spacing (d value) The X-ray powder diffraction pattern is represented by 6.38 (13.85), 10.38 (8.51), 10.75 (8.23), 14.49 (6.11), 15.07 (5.88), 15.58 (5.69), 16.23 (5.46), 17.84 (4.97). , 18.81 (4.72), 19.97 (4.44), 20.77 (4.27), 22.12 (4.02), 23.19 (3.83), 24.12 (3.69), 25.51 (3.49), 26.62 (3.35), 27.38 (3.26), 28.56 (3.12) , 29.91 (2.99) has characteristic peaks.

In the method for producing a type I crystal of the present invention, the form of the compound of the formula (I) which can be used as a raw material is not particularly limited, and any crystal form or amorphous solid can be used, and the type I crystal of the compound of the formula (I) of the present invention The preparation method is:

With some lower organic solvents, preferred are alcohols having a carbon number of 3 or less; more preferably methanol is used as a recrystallization solvent for the compound of the formula (I).

Specifically, the method for preparing Form I crystals of the compound of formula (I) provided by the present invention comprises the steps of:

(1) heating and dissolving a solid of the compound of the formula (I) in any form in an appropriate amount of an organic solvent Part of the solvent is distilled off;

(2) Filtration, washing, and drying.

In a preferred embodiment of the present invention, in the step (1), the organic solvent is selected from the group consisting of alcohols having a carbon number of 3 or less, and further preferably the organic solvent is methanol.

The method of recrystallization differs from the usual recrystallization operation method. After the compound of the formula (I) in any form is heated and dissolved in an organic solvent, a part of the solvent is removed by atmospheric distillation, and after completion of the crystallization, it is dried by filtration to obtain a desired crystal. The crystals to be collected are usually dried under vacuum at a temperature of about 30 to 100 ° C, preferably 40 to 60 ° C, to obtain an effect of removing the recrystallization solvent.

The crystal form of the type I crystal of the obtained compound of the formula (I) was examined by differential scanning calorimetry (DSC) and X-ray diffraction pattern measurement, and the solvent residue of the obtained crystal was examined.

The type I crystal of the compound of the formula (I) prepared according to the process of the present invention does not contain or contains only a relatively low amount of residual solvent, and meets the requirements of the national pharmacopoeia for the residual solvent of the pharmaceutical product, so that the crystal of the present invention can be better. The ground is used as a pharmaceutically active ingredient.

In another aspect, the present invention provides a pharmaceutical composition comprising a crystalline form I of the compound of formula (I), said composition further comprising at least one pharmaceutically acceptable carrier, said pharmaceutically acceptable carrier It may be selected from at least one of lactose, mannitol, microcrystalline cellulose, croscarmellose sodium, sodium carboxymethyl starch, hydroxypropylmethylcellulose, povidone, and magnesium stearate. The content of the type I crystal in the pharmaceutical composition provided by the present invention is from 0.5 mg to 200 mg.

Another aspect of the invention relates to the use of a compound of the formula (I) of the invention, Form I, or a pharmaceutical composition of the invention, for the manufacture of a medicament for the treatment of a disease associated with JAK kinase. The disease is preferably rheumatoid and rheumatoid arthritis.

DRAWINGS

Figure 1 shows an X-ray powder diffraction pattern of a type I crystal of a compound of formula (I) (represented by the code SHR0302 in the figure).

Figure 2 shows a DSC pattern of the Form I crystal of the compound of formula (I).

Figure 3 shows an X-ray powder diffraction pattern of an amorphous solid of the compound of formula (I).

Figure 4 shows a DSC pattern of an amorphous solid of the compound of formula (I).

detailed description

The invention is explained in more detail below with reference to the embodiments, which are intended to illustrate the technical scope of the invention and not to limit the scope and scope of the invention.

Test instrument used in the experiment

1, DSC spectrum

Instrument model: Mettler Toledo DSC 1 Stare ^e System

Purge gas: nitrogen

Heating rate: 10.0 ° C / min

Temperature range: 40-300 ° C

2. X-ray diffraction spectrum

Instrument model: D/Max-RA Japan Rigaku X-ray powder diffractometer

Ray: Monochrome Cu-Kα ray

Scanning mode: θ/2θ, scanning range: 2-40°

Voltage: 40KV current: 40mA

Example 1. A sample of the compound of formula (I) was prepared according to the method of Example 2 of the patent (PCT Application No. PCT/CN2014/076794).

(3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine Preparation of 4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogensulfate (Formula I)

Into a 10 L reaction flask, put (3aR, 5s, 6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2] , 3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide 140g (0.34 mol), added anhydrous methanol 350g, dichloromethane 2.0kg, suspension and stirring 34.8 g (0.36 mol) of sulfuric acid was slowly added dropwise at room temperature, the reaction solution was dissolved, and the reaction was stirred for 30 min. The insoluble material was removed by filtration, and the filtrate was concentrated to dryness under reduced pressure and dried to give 135 g to 168 g of desired product.

MS m/z (ESI): 415.1651 [M+1].

^{1 H NMR (400MHz, DMSO-} d6): δ12.75 (s, 1H), 11.04 (s, 1H), 8.37 (s, 1H), 7.41-7.42 (t, 1H), 6.89 (s, 1H), 5.15-5.19(m,1H), 3.89(s,3H), 3.68-3.70(m,2H), 3.38-3.40(m,2H), 3.29(s,3H),2.95(s,2H),2.09- 2.16(m, 2H), 1.92-1.97 (m, 2H)

Example 2, the crystal form of the sample of the measurement example 1 was measured.

The X-ray diffraction spectrum of the solid sample prepared in Example 1 is shown in Fig. 3, and the characteristic peak of the amorphous form is shown. The DSC spectrum is shown in Fig. 4, and no melting characteristic absorption peak is observed below 300 ° C, and the product is determined as follows. Amorphous solid.

Example 3

(1.0 g, 2.4 mmol) of the compound of the formula (I) (obtained according to the preparation method of Example 1) was added to a 250 ml single-mouth bottle, 100 ml of methanol was added thereto, and the mixture was heated to reflux to reflux, and refluxing was continued for 10 min, and about 90 ml of methanol was distilled off under normal pressure. A large amount of a white solid was precipitated, filtered while hot, and dried to yield 784 mg of white solid. The X-ray diffraction spectrum of the crystal sample is shown in Fig. 1. The crystals are at about 6.38 (13.85), 10.38 (8.51), 10.75 (8.23), 14.49 (6.11), 15.07 (5.88), 15.58 (5.69), 16.23 (5.46), 17.84 (4.97), 18.81 (4.72), 19.97. (4.44), 20.77 (4.27), 22.12 (4.02), 23.19 (3.83), 24.12 (3.69), 25.51 (3.49), 26.62 (3.35), 27.38 (3.26), 28.56 (3.12), 29.91 (2.99) Characteristic peaks. The DSC spectrum is shown in Fig. 2, which has a sharp melting endothermic peak of 220.23 ° C, and this crystal form is defined as the I crystal form.

Example 4

The amorphous sample prepared in Example 1 and the Form I crystalline product obtained in Example 3 were separately placed in an open position, and examined under illumination (4,500 Lux), heated (40 ° C, 60 ° C), and high humidity (RH 75%, Stability of the sample under RH90%) conditions. The sampling time was 5 days and 10 days, and the purity of HPLC was shown in Table 1.

Table 1 Comparison of the stability of the compound type I crystal and amorphous sample of formula (I)

The stability study showed that the compound of formula (I) type I crystal and amorphous sample were open. Under the condition of mouth placement, the stability under light, high temperature and high humidity conditions showed that high humidity had little effect on the two, but under the conditions of light and high temperature, the stability of type I crystal was significantly better than none. Stereotype the sample.

Claims

(3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d Pyrimidine-4-yl)amino) hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogensulfate Form I crystal characterized by Cu-Ka radiation, resulting in a 2θ angle and crystal plane An X-ray powder diffraction pattern represented by a pitch having an X-ray powder diffraction pattern as shown in Figure 1, wherein at about 6.38 (13.85), 10.38 (8.51), 10.75 (8.23), 14.49 (6.11), 15.07 (5.88), 15.58 (5.69), 16.23 (5.46), 17.84 (4.97), 18.81 (4.72), 19.97 (4.44), 20.77 (4.27), 22.12 (4.02), 23.19 (3.83), 24.12 (3.69), 25.51 (3.49), 26.62 (3.35), 27.38 (3.26), 28.56 (3.12), 29.91 (2.99) have characteristic peaks.
A (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-) as claimed in claim 1. A method of crystallizing Form I of pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogensulfate, the process comprising the following step:

1) Any crystal form or amorphous (3aR, 5s, 6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-) Pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogensulfate solid dissolved in an appropriate amount of organic solvent, steamed at atmospheric pressure Excluding a part of a solvent, a solid is precipitated, and the organic solvent is selected from the group consisting of alcohols having a carbon number of 3 or less;

2) Filter, wash and dry.
The process according to claim 2, wherein the organic solvent in the step 1) is methanol.
A pharmaceutical composition comprising (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5- according to claim 1. Form I crystal of methyl (7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogensulfate and pharmaceutically acceptable Accepted carrier.
The pharmaceutical composition according to claim 4, characterized in that (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine The content of the type I crystal of -4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogensulfate is from 0.5 mg to 200 mg.
The pharmaceutical composition according to claim 4, wherein the pharmaceutically acceptable carrier is selected from the group consisting of lactose, mannitol, microcrystalline cellulose, croscarmellose sodium, sodium carboxymethyl starch, At least one of hydroxypropylmethylcellulose, povidone, and magnesium stearate.
(3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[] according to claim 1 Form I crystal of 2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogensulfate or the pharmaceutical composition according to claim 4 Use in the preparation of a medicament for the treatment of a disease associated with JAK kinase.
(3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[] according to claim 1 Form I crystal of 2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide hydrogensulfate or the pharmaceutical composition according to claim 4 Use in the preparation of a medicament for the treatment of rheumatoid arthritis and rheumatoid arthritis.